Show simple item record

dc.contributor.authorPadma, Vasantha
dc.contributor.authorFisher, Marc
dc.contributor.authorMoonis, Majaz
dc.date2022-08-11T08:09:26.000
dc.date.accessioned2022-08-23T16:31:08Z
dc.date.available2022-08-23T16:31:08Z
dc.date.issued2005-04-28
dc.date.submitted2008-04-17
dc.identifier.citationExpert Rev Neurother. 2005 Mar;5(2):223-33. <a href="http://dx.doi.org/10.1586/14737175.5.2.223">Link to article on publisher's site</a>
dc.identifier.issn1744-8360 (Electronic)
dc.identifier.doi10.1586/14737175.5.2.223
dc.identifier.pmid15853492
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37573
dc.description.abstractThe current status of thrombolytic therapy approved by the US Food and Drug Administration is intravenous recombinant plasminogen activator given within 3 h of the onset of ischemic stroke. Intra-arterial therapy is possible for up to 6 h but is not Food and Drug Administration-approved for this purpose. Based on current radiologic methods (i.e., magnetic resonance imaging and perfusion computed tomography scans), it is being increasingly realized that the time window for effective thrombolytic therapy is variable, and salvageable tissue in the form of the ischemic penumbra may exist for longer periods of time and could therefore offer a greater time window based on these imaging studies. Development of an effective neuroprotective drug would greatly enhance the stability of the penumbra and offer further opportunities for extending the time window for reperfusion.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15853492&dopt=Abstract ">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1586/14737175.5.2.223
dc.subjectAcute Disease
dc.subjectAnimals
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectDrug Therapy, Combination
dc.subjectExpert Testimony
dc.subjectFibrinolytic Agents
dc.subjectHumans
dc.subjectInjections, Intravenous
dc.subjectMeta-Analysis as Topic
dc.subjectNeuroprotective Agents
dc.subjectPlatelet Glycoprotein GPIIb-IIIa Complex
dc.subjectStreptokinase
dc.subjectStroke
dc.subjectThrombolytic Therapy
dc.subjectTime Factors
dc.subjectTissue Plasminogen Activator
dc.subjectNeurology
dc.subjectNeuroscience and Neurobiology
dc.titleThrombolytic therapy for acute ischemic stroke: 3 h and beyond
dc.typeJournal Article
dc.source.journaltitleExpert review of neurotherapeutics
dc.source.volume5
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/neuro_pp/112
dc.identifier.contextkey492218
html.description.abstract<p>The current status of thrombolytic therapy approved by the US Food and Drug Administration is intravenous recombinant plasminogen activator given within 3 h of the onset of ischemic stroke. Intra-arterial therapy is possible for up to 6 h but is not Food and Drug Administration-approved for this purpose. Based on current radiologic methods (i.e., magnetic resonance imaging and perfusion computed tomography scans), it is being increasingly realized that the time window for effective thrombolytic therapy is variable, and salvageable tissue in the form of the ischemic penumbra may exist for longer periods of time and could therefore offer a greater time window based on these imaging studies. Development of an effective neuroprotective drug would greatly enhance the stability of the penumbra and offer further opportunities for extending the time window for reperfusion.</p>
dc.identifier.submissionpathneuro_pp/112
dc.contributor.departmentDepartment of Neurology
dc.source.pages223-33


This item appears in the following Collection(s)

Show simple item record